6BBV

Crystal Structure of JAK2 in complex with compound 25


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.215 
  • R-Value Work: 0.175 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.

Vazquez, M.L.Kaila, N.Strohbach, J.W.Trzupek, J.D.Brown, M.F.Flanagan, M.E.Mitton-Fry, M.J.Johnson, T.A.TenBrink, R.E.Arnold, E.P.Basak, A.Heasley, S.E.Kwon, S.Langille, J.Parikh, M.D.Griffin, S.H.Casavant, J.M.Duclos, B.A.Fenwick, A.E.Harris, T.M.Han, S.Caspers, N.Dowty, M.E.Yang, X.Banker, M.E.Hegen, M.Symanowicz, P.T.Li, L.Wang, L.Lin, T.H.Jussif, J.Clark, J.D.Telliez, J.B.Robinson, R.P.Unwalla, R.

(2018) J. Med. Chem. 61: 1130-1152

  • DOI: 10.1021/acs.jmedchem.7b01598
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selec ...

    Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling. Our efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis. Through modification of the 3-aminopiperidine linker in tofacitinib, we discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay. Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by X-ray crystallographic analysis. After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clinical candidate for the treatment of JAK1-mediated autoimmune diseases.


    Organizational Affiliation

    Veterinary Medicine Research and Development, Pfizer Inc , 333 Portage Street, Kalamazoo, Michigan 49007, United States.,Chemical Research Development, Pfizer Inc , Eastern Point Road, Groton, Connecticut 06340, United States.,Medicinal Chemistry, Pfizer Inc , 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States.,Medicine Design, Pfizer Inc , 1 Portland Street, Cambridge, Massachusetts 02139, United States.,Medicine Design, Pfizer Inc , 1 Burtt Road, Andover, Massachusetts 01810, United States.,Inflammation and Immunology, Pfizer Inc , 1 Portland Street, Cambridge, Massachusetts 02139, United States.,Medicine Design, Pfizer Inc , Eastern Point Road, Groton, Connecticut 06340, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tyrosine-protein kinase JAK2
A
298Homo sapiensMutation(s): 0 
Gene Names: JAK2
EC: 2.7.10.2
Find proteins for O60674 (Homo sapiens)
Go to Gene View: JAK2
Go to UniProtKB:  O60674
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
D7D
Query on D7D

Download SDF File 
Download CCD File 
A
N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
C14 H21 N5 O2 S
IUEWXNHSKRWHDY-PHIMTYICSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.215 
  • R-Value Work: 0.175 
  • Space Group: P 1
Unit Cell:
Length (Å)Angle (°)
a = 36.380α = 69.03
b = 45.690β = 72.95
c = 49.010γ = 81.60
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
SCALAdata scaling
BUSTERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2017-10-19 
  • Released Date: 2018-01-17 
  • Deposition Author(s): Han, S.

Revision History 

  • Version 1.0: 2018-01-17
    Type: Initial release
  • Version 1.1: 2018-02-21
    Type: Database references
  • Version 1.2: 2018-02-28
    Type: Experimental preparation